Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
about
Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseStriving for optimal bronchodilation: focus on olodaterolDual therapy strategies for COPD: the scientific rationale for LAMA + LABASpecific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary diseaseAirway and Extracellular Matrix Mechanics in COPDDifferential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterolA rational approach to single, dual and triple therapy in COPDPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseAnimal models of COPD: What do they tell us?The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseaseA review of nebulized drug delivery in COPDEfficacy of tiotropium-olodaterol fixed-dose combination in COPDCardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.Tiotropium Bromide/Olodaterol (Stiolto Respimat): Once-Daily Combination Therapy for the Maintenance of COPD.The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studiesBronchodilator reversibility in patients with COPD revisited: short-term reproducibilityEligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by ageUK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD.Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstrDual bronchodilation in COPD: lung function and patient-reported outcomes - a review.Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist.LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.Long-acting muscarinic antagonists.Bronchodilators, receptors and cross-talk: Together is better?Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.
P2860
Q24186411-C81C2626-2620-4D2A-AAE9-1B3FAA94F711Q26752887-63AB6308-D2CE-463C-862D-85AAEB7CB26DQ26752988-10A584CC-A756-4F51-A754-EAD5FFF60EA7Q26770504-348D0F15-9A76-40DE-931B-B1DD38C9E256Q26773109-853D31E6-D11A-4D3B-88F8-D9D387EB8743Q26775244-4B16CAD1-B6E0-44CA-92E7-DBB83FEA1D1CQ26776477-126F8B1B-31D3-4A43-A939-F3581DF76980Q26778685-D5F07B70-2665-47B0-A132-B956572A4298Q26801661-C927E083-36BF-4402-9FEA-2F96C2453A96Q28066451-43217F33-D334-4932-BC37-9428F0CCE8B6Q28068078-0EAAEF1D-DF82-4E77-BED9-BFC5EDD87A4AQ28075295-5D22830E-CCF0-4977-98D6-EB63E494C8FBQ28075367-FC640A75-DAA2-47B9-BB69-275B3037AC7FQ28596651-721B7F85-445A-4736-AAB0-9BEBF9DF6E62Q31165976-96B46F31-289F-427E-941C-7BCBA40C48FEQ33743284-7ED4B718-83BA-46C5-B750-850BCF4806E8Q33890852-0BD74CF0-7B39-4582-AD6E-DD164282FB19Q35766346-21447028-7AEE-4B03-873F-E59AA8990F39Q35802628-CEFE68B5-D17A-45EB-B8DE-01DB48832F07Q35937943-1B921EC1-864B-424C-9294-2B9DAF5C1A8DQ36158846-66E69B9D-BA31-452E-97AF-9D23EA7BAFE7Q36329064-E67B56ED-4D93-45E4-9943-095C56A6F4FCQ36556995-7D875C5E-635C-4847-9445-13C7D027B746Q36557670-D661D1A3-E880-4FB2-8275-6C9F0C2AAFCDQ37229624-D7328BC5-C943-4C94-97E1-40C56FA0CF43Q37229628-D2CF5EAD-C6B3-4080-9CDE-D82B3C74D3BAQ37278903-365F2DBD-EEA2-443F-B688-B2B8F2759E9FQ37283438-07A900B4-5E91-4FAC-A5EB-8A33D57A3A5EQ37397852-03174D26-A784-48F6-9866-C570E0C6BE52Q37409751-DE1AC1C9-763B-4C12-8D9C-13EA42A2FBBAQ37468663-77138E64-C55A-4176-976E-D30BF3FE98AFQ37563982-4D5A223A-57D6-4534-88E4-81230E3F476BQ37573177-4C63DECC-E0C1-4004-867E-2D6650FAEBF9Q37579554-5A56141C-875A-418E-9418-341842805B3DQ38531919-8D32DF4C-5C4E-41C5-9628-35F4C482CC4FQ38537326-893BD63D-38F9-469F-A883-3F611D1DF0FBQ38570698-9FE1DF65-1FAF-461E-8A83-AF1E35BA4D3EQ38570714-FDE81F88-069D-44A4-A17E-4907017AB847Q38586322-86EEF5CD-CAFD-4B99-AF9B-E6609D5BAB5DQ38592062-6534377E-AD69-4517-A283-F24D8F6837C6
P2860
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Tiotropium and olodaterol fixe ...... components in COPD (GOLD 2-4).
@ast
Tiotropium and olodaterol fixe ...... components in COPD (GOLD 2-4).
@en
type
label
Tiotropium and olodaterol fixe ...... components in COPD (GOLD 2-4).
@ast
Tiotropium and olodaterol fixe ...... components in COPD (GOLD 2-4).
@en
prefLabel
Tiotropium and olodaterol fixe ...... components in COPD (GOLD 2-4).
@ast
Tiotropium and olodaterol fixe ...... components in COPD (GOLD 2-4).
@en
P2093
P2860
P1476
Tiotropium and olodaterol fixe ...... components in COPD (GOLD 2-4).
@en
P2093
Alan Hamilton
Antony Veale
Emilio Pizzichini
Eric Bateman
Eric Derom
François Maltais
Gary Ferguson
Henrik Watz
Jacques Hébert
P2860
P304
P356
10.1183/09031936.00136014
P50
P577
2015-01-08T00:00:00Z